The Effect of Lactoferrin and Dosing Regimen on Iron Absorption From a Maize-based Porridge in Kenyan Infants

NCT ID: NCT03617575

Last Updated: 2020-05-13

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-11

Study Completion Date

2019-03-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to measure iron absorption from maize-based porridge fortified with either apo-lactoferrin, holo-lactoferrin or ferrous sulfate and to test whether there is an effect of these. Additionally, iron absorption from maize-based porridge containing 12 mg ferrous sulfate will be measured when consumed every other day versus every third day.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Infants and young children in sub-Saharan Africa have high rates of iron deficiency anemia (IDA), which adversely affects their growth and cognitive development. In-home iron fortification of complementary foods using micronutrient powders (MNPs) reduces risk for IDA by ensuring that the iron needs of infants and young children are met without changing their traditional diet. Oral iron syrups, typically containing iron as ferrous sulfate, can also be given to prevent/correct IDA. However, iron absorption from MNPs and iron syrups, particularly when given with complementary foods high in inhibitors of iron absorption, is low. Thus, there is a need to find iron formulations with higher bioavailability for use in African infants. In a recent trial in Kenya, the investigators demonstrated that a prebiotic could improve iron bioavailability from an iron-containing MNP.

In this study, the investigators plan to assess the human milk compound lactoferrin (Lf) as a possible enhancer of iron absorption. Lf is an important iron-binding protein in human milk, which has been thought to be responsible for the high bioavailability of breast-milk iron. It has many biological functions, including iron absorption, antimicrobial activity, immunomodulatory effects and stimulatory effect on cell proliferation. Lf has different iron binding statuses: the iron free form (apo-Lf) and the iron-saturated form (holo-Lf). One of the two main biological activities of Lf provided by the diet is the control of iron uptake, which is mediated by the Lf receptor (LFR) as undigested Lf can bind to LFR and facilitate the uptake of iron. Therefore, Lf may be a nutritional iron source and may enhance iron absorption in infants. To evaluate the possible role of Lf on the availability of iron, iron absorption will be measured from bovine Lf (bLf). BLf has GRAS (generally considered as safe) status by the US Food and Drug Administration.

To optimize iron absorption, timing of supplementation might as well be important. Hepcidin, a key regulator of systemic iron balance and a single dose of iron can increase hepcidin levels and potentially inhibit iron absorption from a second dose, consumed close in time to the first dose. The investigators will conduct two studies, where 24 infants aged 3-14 months in Msambweni, Kenya, will be enrolled. In study 1, on three alternate mornings, these infants will consume maize porridge containing a low iron dose (1.5 mg) to compare iron absorption between meals with apo-Lf, holo-Lf and ferrous sulfate (FeSO4) as a reference; and whether the addition of either apo- or holo-Lf has a beneficial effect on iron absorption. The investigators hypothesize that iron absorption will be higher when holo-Lf is present in the meal compared to apo-Lf. In study 2, the investigators want to compare two different dosing regimens, in which they measure iron absorption after one-day washout period and after a two-day washout period, and hypothesize that absorption will be higher after 2 days of washout.

The data from this project will provide valuable information towards the development of new, highly bioavailable iron formulations and dosing regimen that is most efficient.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Iron-deficiency

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

apo-Lactoferrin

unsaturated (= no iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal A1

Group Type PLACEBO_COMPARATOR

apo-Lactoferrin

Intervention Type DIETARY_SUPPLEMENT

1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)

holo-Lactoferrin

saturated (= contains a certain amount of iron) form of Lactoferrin Lactoferrin is a bovine milk protein Test Meal B1

Group Type PLACEBO_COMPARATOR

holo-Lactoferrin

Intervention Type DIETARY_SUPPLEMENT

1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge

FeSO4

Ferrous sulfate = FeSO4 acting as the reference Test Meal C1

Group Type PLACEBO_COMPARATOR

FeSO4

Intervention Type DIETARY_SUPPLEMENT

1.5 mg FeSO4 as 54Fe in a maize porridge

1. FeSO4

Ferrous sulfate = FeSO4 Test Meal A2

Group Type PLACEBO_COMPARATOR

1. FeSO4

Intervention Type DIETARY_SUPPLEMENT

10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge

FeSO4 after 1 day break

Ferrous sulfate = FeSO4 Test Meal B2

Group Type PLACEBO_COMPARATOR

FeSO4 after 1 day break

Intervention Type DIETARY_SUPPLEMENT

10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period

FeSO4 after 2 day break

Ferrous sulfate = FeSO4 Test Meal C2

Group Type PLACEBO_COMPARATOR

FeSO4 after 2 day break

Intervention Type DIETARY_SUPPLEMENT

10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

apo-Lactoferrin

1.41 g of apo-Lactoferrin will be given together with 1.42 mg FeSO4 (0.08 mg of iron naturally in apo-Lf \[total of 1.5 mg iron\]) in a maize porridge (extrinsically labeled)

Intervention Type DIETARY_SUPPLEMENT

holo-Lactoferrin

1.41 g of holo-Lactoferrin (intrinsically labeled with 1.5 mg 57Fe) will be given together in a maize porridge

Intervention Type DIETARY_SUPPLEMENT

FeSO4

1.5 mg FeSO4 as 54Fe in a maize porridge

Intervention Type DIETARY_SUPPLEMENT

1. FeSO4

10 mg 56Fe + 2 mg 54Fe Is the 1. FeSO4 meal in maize porridge

Intervention Type DIETARY_SUPPLEMENT

FeSO4 after 1 day break

10 mg 56Fe + 2 mg 57Fe Is the 2. FeSO4 in maize porridge with a 1 day washout period

Intervention Type DIETARY_SUPPLEMENT

FeSO4 after 2 day break

10 mg 56Fe + 2 mg 58Fe Is the 3. FeSO4 in maize porridge with a 2 day washout period

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age of 3-14 months at baseline
* Complementary feeding of the infant has already started
* Assessment of good health as assessed by professional staff at Msambweni District Hospital
* The caregiver is willing to participate in the study
* The informed consent form has been read and signed by the caregiver (or has been read out to the caregiver in case of illiteracy)
* Willingness of the caregiver to provide five blood samples from their child in total during the studies during the visits at the hospital
* Residence in the study for the period of the study

Exclusion Criteria

* Hb \<70 g/L
* Severe underweight (waz \<-3)
* Severe wasting (whz \<-3)
* Chronic or acute illness or other conditions that in the opinion of the principle investigator or co-researchers would jeopardize the safety or rights of a participant in the trial or would render the participant unable to comply with the protocol
* Participants taking part in other studies requiring the drawing of blood
* Regular intake (\>2 days) of iron-containing mineral and vitamin supplements or fortified foods within the last 2 months
Minimum Eligible Age

3 Months

Maximum Eligible Age

14 Months

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swiss Federal Institute of Technology

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Prof. Michael B. Zimmermann

Head of Laboratory of Human Nutrition

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Msambweni County Referral Hospital

Msambweni, Kwale County, Kenya

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Kenya

References

Explore related publications, articles, or registry entries linked to this study.

Mikulic N, Uyoga MA, Mwasi E, Stoffel NU, Zeder C, Karanja S, Zimmermann MB. Iron Absorption is Greater from Apo-Lactoferrin and is Similar Between Holo-Lactoferrin and Ferrous Sulfate: Stable Iron Isotope Studies in Kenyan Infants. J Nutr. 2020 Dec 10;150(12):3200-3207. doi: 10.1093/jn/nxaa226.

Reference Type DERIVED
PMID: 32886113 (View on PubMed)

Uyoga MA, Mikulic N, Paganini D, Mwasi E, Stoffel NU, Zeder C, Karanja S, Zimmermann MB. The effect of iron dosing schedules on plasma hepcidin and iron absorption in Kenyan infants. Am J Clin Nutr. 2020 Oct 1;112(4):1132-1141. doi: 10.1093/ajcn/nqaa174.

Reference Type DERIVED
PMID: 32678434 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Fe_LF

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Iron-fortified Whole Maize Flour Trial
NCT00386074 COMPLETED PHASE2
Baby Iron Bioavailability Study
NCT03754543 COMPLETED NA